CMS Recommends Against Low-Dose CT Lung Cancer Screening

Share this content:
  • Advanced Stage NSCLC
  • Fluorodeoxyglucose FDG-PET Scan
  • Bronchopulmonary SCLC
  • PET/CT Fusion Imaging
  • 3D CT Scan Model
  • MRI Scan Showing SCLC
  • Lung Tumor Invading an Alveolus
  • Masses in Both Lungs
  • Small Cell Lung Cancer

Lung Cancer

CMS Recommends Against Low-Dose CT Lung Cancer Screening
CMS Recommends Against Low-Dose CT Lung Cancer Screening

(HealthDay News) -- The Medicare Evidence Development and Coverage Advisory Committee (MEDCAC) recently recommended against screening of high-risk, older adults for lung cancer using low-dose computed tomography (CT), according to a news release from the American Academy of Family Physicians (AAFP).

The news release states that the recommendation by MEDCAC parallels the AAFP's lung cancer screening recommendation, citing insufficient evidence to recommend for or against lung cancer screening based on age and smoking history. 

RELATED: AAFP Recommends Against Low-dose CT Screening for Lung Cancer

However, the MEDCAC recommendation counters the U.S. Preventive Services Task Force (USPSTF) decision to screen high-risk older adults (adults aged 55 to 80 years who have a 30 pack-year smoking history and currently smoke or have quit within the past 15 years) with low-dose CT.

Outlining the AAFP's position, Doug Campos-Outcalt, MD, spoke at MEDCAC, raising concerns with the USPSTF recommendation, according to the news release. 

Firstly, he said the National Lung Screening Trial, which formed the basis of the USPSTF recommendation, had conditions that were not reproducible in community settings and he had some concern with the study's design of modeling predictions. 

RELATED: USPSTF: Low-Dose CT Screening Reduces Lung Cancer

Additionally, the 20% reduction in lung cancer mortality seen in the study was likely a best-case scenario, he said. Radiation from repeat screening was also a concern, with the possibility of 25 lifetime scans in the targeted, high-risk group. 

The Centers for Medicare & Medicaid Services will make a final coverage decision in the fall.

"With widespread community screening, there are likely to be more complications and deaths, raising more doubts about all-cause mortality," Campos-Outcalt told the AAFP News.

For more information, click here.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs